ML
BMRN icon

McAdam LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

McAdam LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-210
Closed -$21K – 120
2018
Q3 		$21K Hold
210
– – 0.01% 246
2018
Q2 		$20K Hold
210
– – 0.01% 240
2018
Q1 		$17K Buy
+210
New +$18K 0.01% 262

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

McAdam LLC's BMRN Position: Q4 2018 in Review

McAdam LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 210 shares — an estimated $21K sold.

McAdam LLC first reported a position in BMRN in Q1 2018 and held it in 3 quarters. The position peaked at $21K in Q3 2018. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • McAdam LLC reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • McAdam LLC sold 210 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $21K.
  • McAdam LLC first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • McAdam LLC's BioMarin Pharmaceuticals position peaked at $21K in Q3 2018.
  • 473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.